245 related articles for article (PubMed ID: 37837401)
1. H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy.
Zhong C; Xie Z; Duan S
Clin Transl Med; 2023 Oct; 13(10):e1445. PubMed ID: 37837401
[TBL] [Abstract][Full Text] [Related]
2. Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets.
Alahdal M; Elkord E
Clin Transl Med; 2023 Sep; 13(9):e1425. PubMed ID: 37735815
[TBL] [Abstract][Full Text] [Related]
3. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA DLGAP1-AS1 modulates the development of non-small-cell lung cancer via the microRNA-193a-5p/DTL axis.
Pan X; Chen S; Ye L; Xu S; Wang L; Sun Y
Lab Invest; 2022 Nov; 102(11):1182-1191. PubMed ID: 36183046
[TBL] [Abstract][Full Text] [Related]
5. [Effects of Interference with UCA1 and Inhibition of miR-185-5p on Activation, Autophagy and Survival of β-Catenin Pathway in Non-small Cell Lung Cancer].
Yang Y; Liu XR; Jin Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):157-163. PubMed ID: 31106532
[TBL] [Abstract][Full Text] [Related]
6. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
7. The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1.
Ma H; Yuan L; Li W; Xu K; Yang L
J Cell Biochem; 2018 Nov; 119(10):8325-8335. PubMed ID: 29968942
[TBL] [Abstract][Full Text] [Related]
8. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.
Yuwen DL; Sheng BB; Liu J; Wenyu W; Shu YQ
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2650-2658. PubMed ID: 28678319
[TBL] [Abstract][Full Text] [Related]
9. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
10. LncRNA LINC00240 suppresses invasion and migration in non-small cell lung cancer by sponging miR-7-5p.
Ku GW; Kang Y; Yu SL; Park J; Park S; Jeong IB; Kang MW; Son JW; Kang J
BMC Cancer; 2021 Jan; 21(1):44. PubMed ID: 33422052
[TBL] [Abstract][Full Text] [Related]
11. The lncRNA XIST/miR-125b-2-3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer.
Zeng ZL; Lu JH; Wang Y; Sheng H; Wang YN; Chen ZH; Wu QN; Zheng JB; Chen YX; Yang DD; Yu K; Mo HY; Hu JJ; Hu PS; Liu ZX; Ju HQ; Xu RH
Cancer Med; 2021 Apr; 10(7):2423-2441. PubMed ID: 33666372
[TBL] [Abstract][Full Text] [Related]
12. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p.
Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF
Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791
[TBL] [Abstract][Full Text] [Related]
13. Co-expression profiling of plasma miRNAs and long noncoding RNAs in gastric cancer patients.
Ghaedi H; Mozaffari MAN; Salehi Z; Ghasemi H; Zadian SS; Alipoor S; Hadianpour S; Alipoor B
Gene; 2019 Mar; 687():135-142. PubMed ID: 30447342
[TBL] [Abstract][Full Text] [Related]
14. Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
Li LL; Qu LL; Fu HJ; Zheng XF; Tang CH; Li XY; Chen J; Wang WX; Yang SX; Wang L; Zhao GH; Lv PP; Zhang M; Lei YY; Qin HF; Wang H; Gao HJ; Liu XQ
Oncotarget; 2017 Jul; 8(28):45399-45414. PubMed ID: 28514730
[TBL] [Abstract][Full Text] [Related]
15. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
[TBL] [Abstract][Full Text] [Related]
16. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G
Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923
[TBL] [Abstract][Full Text] [Related]
17. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p.
Wu W; Zhao Y; Gao E; Li Y; Guo X; Zhao T; He W; Zhang H
J Cell Mol Med; 2020 Jan; 24(1):441-450. PubMed ID: 31721438
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.
Liu J; Zhou WY; Luo XJ; Chen YX; Wong CW; Liu ZX; Bo Zheng J; Yu Mo H; Chen JQ; Li JJ; Zhong M; Xu YH; Zhang QH; Pu HY; Wu QN; Jin Y; Wang ZX; Xu RH; Luo HY
Clin Transl Med; 2023 Sep; 13(9):e1410. PubMed ID: 37712124
[TBL] [Abstract][Full Text] [Related]
19. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
Wei S; Wang K; Huang X; Zhao Z; Zhao Z
Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
[TBL] [Abstract][Full Text] [Related]
20. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
He Y; Jiang X; Duan L; Xiong Q; Yuan Y; Liu P; Jiang L; Shen Q; Zhao S; Yang C; Chen Y
Mol Cancer; 2021 Dec; 20(1):156. PubMed ID: 34856993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
